The Structural Genomics Consortium: A knowledge platform for drug discovery: A summary

Molly Morgan Jones ; Sophie Castle-Clarke ; Daniel Brooker ; Edward Nason ; Farah Huzair ; Joanna Chataway

RAND Corporation

RAND Corporation

关键词: Genomic Medicine;    Biotechnology;    Intellectual Property;    Science;    Technology;    and Innovation Policy;    Pharmaceutical Drugs;   

DOI  :  10.7249/RR512z1
RP-ID  :  RR-512/1-SGC

学科分类：自然科学（综合）

美国|英语

来源: RAND Corporation Published Research

【 摘 要 】

The Structural Genomics Consortium (SGC) supports drug discovery efforts through a unique, open access model of public-private collaboration. This report summarises the results of an independent evaluation of the Structural Genomics Consortium, an open access model of public-private collaboration, conducted by RAND Europe with the Institute on Governance. The evaluation aimed to establish the role of the SGC within the wider drug discovery and PPP landscape, assessing the merits of the SGC open access model relative to alternative models of funding R&D in this space, as well as the key trends and opportunities in the external environment that may impact on the future of the SGC. It also established the incentives and disincentives for investment, strengths and weaknesses of the SGC's model, and the opportunities and threats the SGC will face in the future. This enabled us to assess the most convincing arguments for funding the SGC at present; important trade-offs or limitations that should be addressed in moving towards the next funding phase; and whether funders are anticipating changes either to the SGC or the wider PPP landscape. Finally, we undertook a quantitative analysis to ascertain what judgements can be made about the SGC's past and current performance track record, before unpacking the role of the external environment and particular actors within the SGC in developing scenarios for the future.